INSMED Inc
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Insmed is a biopharmaceutical company that develops and markets treatments for serious and rare diseases, including its approved therapy for nontuberculous mycobacterial lung disease, alongside a pipeline targeting bronchiectasis, pulmonary and inflammatory conditions.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Flammer Martina M.D.Chief Medical Officer | Sell | $2.37M | 18,278at $129.40 | Aug 6, 2026 |
| Flammer Martina M.D.Chief Medical Officer | Sell | $1.13M | 8,895at $127.00 | Aug 6, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
| Member | Chamber | Type | Amount | Date |
|---|---|---|---|---|
| Josh GottheimerNJ05 | House | Sell | $1,001 - $15,000 | Jun 10, 2026 |
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable INSM activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.